Suspected Giant Cell Arteritis
Age ≥50 with: new headache, jaw claudication, scalp tenderness, visual symptoms, PMR symptoms, unexplained elevated ESR/CRP
All Pathways
OphthalmologyEmergency
Giant Cell Arteritis (GCA) and Arteritic AION Management
Giant Cell Arteritis (GCA) and Arteritic AION Management: Suspected Giant Cell Arteritis → Visual Symptoms Present? → OPHTHALMIC EMERGENCY → Laboratory ...
Pathway Overview
15 steps
Algorithm Steps
15 total
01Start 02Decision Visual Symptoms Present?
Any: vision loss, amaurosis fugax, diplopia, RAPD, optic disc edema/pallor
03Action OPHTHALMIC EMERGENCY
Vision-threatening GCA requires immediate high-dose IV steroids
- IV Methylprednisolone 500-1000mg/day x 3 days
- THEN oral prednisone 1mg/kg/day (max 60-80mg)
- DO NOT delay treatment to obtain biopsy
- Admit for IV therapy if outpatient not feasible
04Action Laboratory Workup
Send immediately - do not delay steroids for results
- ESR - typically elevated >50mm/hr (often >100)
- CRP - sensitive marker, usually markedly elevated
- CBC - normocytic anemia, thrombocytosis common
- LFTs - may see elevated ALP
- Note: ~5% have normal ESR/CRP
05Action Consider Imaging
Temporal artery ultrasound or other modalities
- Temporal artery ultrasound: 'halo sign' suggestive
- MRI/MRA: vessel wall enhancement
- PET-CT: for large vessel involvement
- Imaging does NOT replace biopsy
06Decision Clinical Response to Steroids?
Most patients improve markedly within 24-72 hours
07Action Good Response - Taper Steroids
Gradual taper with monitoring
- After 2-4 weeks at initial dose, begin taper
- Typical: reduce by 10mg every 2 weeks until 40mg
- Then slower: 5mg every 2-4 weeks until 15-20mg
- Then very slow: 1-2.5mg/month
- Monitor ESR/CRP with each reduction
- Total treatment usually 1-2+ years
08Action Consider Steroid-Sparing Therapy
For relapsing disease or unable to taper
- Tocilizumab 162mg SC weekly - FDA approved for GCA
- Significantly reduces relapse and cumulative steroid dose
- Screen for latent TB, hepatitis before starting
- Monitor LFTs, lipids, neutrophils
- Alternative: Methotrexate 15-25mg/week
09Action Long-term Monitoring
GCA requires prolonged follow-up
- Monitor for steroid side effects (glucose, BP, osteoporosis)
- Start PPI, calcium/vitamin D, consider bisphosphonate
- ESR/CRP with each taper step
- Watch for aortic aneurysm (annual CXR or CT if concerning)
- Relapse common - may need re-escalation
10Outcome Remission Achieved
Steroids tapered/stopped, continued monitoring for relapse
11Outcome Rheumatology Co-management
Complex/refractory cases benefit from rheumatology involvement
12Action Poor/No Response
Reconsider diagnosis or add steroid-sparing agent
- Re-evaluate: is this truly GCA?
- Consider other causes of visual loss
- Tocilizumab (IL-6 inhibitor) - ACR recommended for relapsing/refractory
- Methotrexate as alternative
- Path rejoins step 08Shared downstream outcome
13Warning ⚠️ Vision Loss Can Progress
Up to 10% of patients may have further vision loss despite steroids, especially in first 1-2 weeks
- Path rejoins step 09Shared downstream outcome
14Action Temporal Artery Biopsy
Gold standard for diagnosis
- Arrange within 2 weeks of starting steroids
- Sensitivity decreases after 2-4 weeks of treatment
- Unilateral adequate; bilateral if high suspicion and negative
- Specimen length ≥1-2cm
- Negative biopsy does not rule out GCA
- Path rejoins step 06Shared downstream outcome
15Action GCA Without Visual Loss
Start oral corticosteroids promptly
- Prednisone 40-60mg daily (1mg/kg, max 60mg)
- Or equivalent glucocorticoid
- Most patients respond within 24-72 hours
- Path rejoins step 04Shared downstream outcome
Guideline Source
2021 ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Clinical judgment required for diagnosis - no single test is definitive
- Steroid taper requires individualization based on response
- Tocilizumab may mask infection and requires monitoring
- Does not address large vessel/aortic GCA in detail
Applicable Regions
USEUGlobal
EU: EULAR 2018 + BSR 2020 guidelines
US: ACR/VF 2021 current standard
Global: Similar principles worldwide
Version 1Next review: 2028-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Giant Cell Arteritis (GCA) and Arteritic AION Management?
The Giant Cell Arteritis (GCA) and Arteritic AION Management is a emergency clinical algorithm for Ophthalmology. It provides a structured decision tree to guide clinical decision-making, based on 2021 ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis.
What guideline is the Giant Cell Arteritis (GCA) and Arteritic AION Management based on?
This algorithm is based on 2021 ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis (DOI: 10.1002/art.41774).
What are the limitations of the Giant Cell Arteritis (GCA) and Arteritic AION Management?
Known limitations include: Clinical judgment required for diagnosis - no single test is definitive; Steroid taper requires individualization based on response; Tocilizumab may mask infection and requires monitoring; Does not address large vessel/aortic GCA in detail. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Giant Cell Arteritis (GCA) and Arteritic AION Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free